InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics
PR Newswire•06/11/2026•16:05 ET
0
Key Highlights
- ➤Merger with Mentari Therapeutics completed; combined company renamed Mentari Therapeutics
- ➤Approximately $490 million raised in private financings, including $50 million notes conversion
- ➤Shares expected to begin Nasdaq trading November 9 under ticker MTRI
- ➤Each pre-merger Mentari share converted into approximately 0.20065 combined-company shares
- ➤Company completed 1-for-10 reverse stock split and Nevada redomestication
InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics PR Newswire
Shares expected to trade on Nasdaq under the ticker symbol "MTRI" commencing November 9, 2026
Get started
Create a free account to read the full story.